Senetek PLC To Present at The Rodman and Renshaw 9th Annual Healthcare Conference
Thursday November 1, 9:30 am ET
NAPA, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNTKY - News), a specialty life sciences company engaged in the study of senescense, the science of aging with an initial focus on skincare and dermatological therapeutics, today announced that Mr. Frank J. Massino, Chairman and Chief Executive Officer of Senetek PLC, Professor Brian Clark, Chief Scientific Officer and Mr. William O'Kelly, Chief Financial Officer, will present a company update at the Rodman and Renshaw 9th Annual Healthcare Conference in New York City on Tuesday, November 6, 2007 at 4:45 pm ET.
ADVERTISEMENT
A live audio webcast of the presentation will be accessible through the Rodman and Renshaw website, rodmanandrenshaw.com. The presentation slides will be available on the Senetek website senetekplc.com immediately following the webcast.
About Senetek PLC
Senetek PLC (OTC Bulletin Board: SNTKY - News) is a specialty life sciences company engaged in the study of senescense, the science of aging with an initial focus on skincare and dermatological therapeutics. Senetek recently announced a Marketing Collaboration Agreement for its second-generation cytokinin with Triax Aesthetics LLC which will guarantee a minimum of $10.8 million in revenues in 2008 and granted Valeant Pharmaceuticals a paid up license for Senetek's first generation patented skin care active ingredient Kinetin and its analog Zeatin in return for $21 million cash and forgiveness of $6 million prepaid royalty credit, and is negotiating third party license agreements for new patent-pending second generation dermatological active ingredients and is completing development of a number of additional compounds. In addition, Senetek has entered into exclusive licenses for Europe and North America, respectively, for Invicorp®, has an exclusive manufacturing distributorship for its proprietary diagnostic monoclonal antibodies, and recently sold, with retained rights of profit participation, its patented drug delivery system, Reliaject®. For more information, visit the company's website at senetekplc.com. |
